GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Univo Pharmaceuticals Ltd (XTAE:UNVO-M) » Definitions » Capex-to-Operating-Income

Univo Pharmaceuticals (XTAE:UNVO-M) Capex-to-Operating-Income : 0.00 (As of Jun. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Univo Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Univo Pharmaceuticals's Capital Expenditure for the three months ended in Jun. 2022 was ₪-1.32 Mil. Its Operating Income for the three months ended in Jun. 2022 was ₪-20.94 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Univo Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Univo Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Univo Pharmaceuticals Capex-to-Operating-Income Chart

Univo Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only - - - 98.05 -

Univo Pharmaceuticals Quarterly Data
Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 - - - -

Competitive Comparison of Univo Pharmaceuticals's Capex-to-Operating-Income

For the Biotechnology subindustry, Univo Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Univo Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Univo Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Univo Pharmaceuticals's Capex-to-Operating-Income falls into.


;
;

Univo Pharmaceuticals Capex-to-Operating-Income Calculation

Univo Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-8.255) / -0.551
=N/A

Univo Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Jun. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.316) / -20.939
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Univo Pharmaceuticals  (XTAE:UNVO-M) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Univo Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Univo Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Univo Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Harshar 20, Ashkelon, ISR, 7878329
Univo Pharmaceuticals Ltd is engaged in designing & developing drugs for the treatment of brain disorders. The company provides cannabis-based products for distribution and export to the international markets.

Univo Pharmaceuticals Headlines

No Headlines